Back to top
more

Charles River Laboratories International (CRL)

(Real Time Quote from BATS)

$182.48 USD

182.48
323,783

+1.52 (0.84%)

Updated Nov 4, 2024 03:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

Charles River (CRL) Advances in Gene Therapy With Vigene Buyout

The consolidation between Charles River (CRL) and Vigene is set to establish an end-to-end, gene-modified cell therapy solution in the United States.

What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?

Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Duke Energy (DUK) Brand Starts Building 250MW Solar Project

Duke Energy (DUK) announces the 250-MW Pisgah Ridge Solar project will supply power to three corporations, once its construction is completed by 2022-end.

Charles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates

Charles River (CRL) delivered earnings and revenue surprises of 15.53% and 3.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Neena Mishra headshot

ETF Strategies to Hedge Against Inflation

Here are some ways to protect your portfolio from rising inflation.

Teladoc (TDOC) Q4 Loss Widens, Revenues Surpass Estimates

Teladoc's (TDOC) Q4 earnings result reflects revenue gains, more than offset by flared-up expenses.

Company News for Feb 18, 2021

Companies in the news are: CRL, VIR, LODE, CLPS

Charles River Laboratories (CRL) Beats Q4 Earnings and Revenue Estimates

Charles River (CRL) delivered earnings and revenue surprises of 12.74% and 4.63%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Charles River Laboratories (CRL) Reports Next Week: Wall Street Expects Earnings Growth

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is a Beat in the Cards for CVS Health (CVS) in Q4 Earnings?

Through November and December, the resurgence of new COVID-19 cases might have resulted in more COVID-19 tests conducts by CVS Health (CVS).

Higher Testing Volume to Aid LabCorp's (LH) Q4 Earnings

LabCorp's (LH) fourth-quarter base-business performance is expected to have registered slower recovery rate compared to the third quarter.

Why Charles River (CRL) Could Beat Earnings Estimates Again

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Charles River (CRL) is an Incredible Growth Stock: 3 Reasons Why

Charles River (CRL) possesses solid growth attributes, which could help it handily outperform the market.

Charles River (CRL) Soars to 52-Week High, Time to Cash Out?

Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

3 Reasons Growth Investors Will Love Charles River (CRL)

Charles River (CRL) possesses solid growth attributes, which could help it handily outperform the market.

Healthcare Stock Q3 Earnings Due on Oct 29: NVCR, CRL & More

Coronavirus is going to affect the earnings results of healthcare players. While hospitals and health insurers might have suffered the COVID-19 impact, others providing virtual care and COVID-19-related services are likely to have gained from the same.

Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Charles River (CRL) Keep the Earnings Surprise Streak Alive?

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Charles River (CRL) is an Incredible Growth Stock: 3 Reasons Why

Charles River (CRL) possesses solid growth attributes, which could help it handily outperform the market.

Charles River Laboratories (CRL) Q2 Earnings and Revenues Beat Estimates

Charles River (CRL) delivered earnings and revenue surprises of 24.41% and 7.41%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Healthcare Stock Q2 Earnings Roster for Aug 5: HUM, CRL & More

The healthcare sector is expected to have benefited from solid demand for medical products and services in Q2, given the rising incidence of coronavirus cases as well as an ageing U.S. populace.

Should You Buy Charles River Laboratories (CRL) Ahead of Earnings?

Charles River Laboratories (CRL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?

Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Charles River (CRL) Keep the Earnings Surprise Streak Alive?

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks.com featured highlights include: Lowes Companies, Charles River Laboratories International, Agilent Technologies and East West

Zacks.com featured highlights include: Lowes Companies, Charles River Laboratories International, Agilent Technologies and East West